Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Kirsten who wrote (537)	4/3/1998 2:51:00 PM
From: Ariella	Read Replies (3) of 1491

Dear Kirsten, The New York Times Science Section this past Tuesday (3/31/98) had an excellent article on the blood-brain barrier, which is difficult to breach (that's good because it mostly stops bad things from getting into your brain tissue and bad because beneficial drugs also can't get in). HU-211 is able to cross the BBB. It's a synthetic cannabinoid compound designed to avoid the psychotropic side-effects of cannobinimetic agents. (In layman's terms -- grass without the high) and is an exciting drug in terms of its ability to ameliorate brain swelling in traumatic accidents. It also may have potential to be useful in treatment of MS. Here is an article with pictures on the issue of the BBB. Notice mention of a Dr. Nicholas Bodor from the U. of Florida. It's his work behind Alrex and Lotemax, which the company has licensed. The HU in HU-211 stands for Hebrew University in Israel, the academic affiliation of the drug's inventor, Dr. Raphael Mechoulam. HU-211 is also licensed by PARS. pilot.msu.edu Hope you find them interesting. Ariella

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next